Overview

Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
This study will compare the efficacy and safety of exenatide versus placebo in adults whose diabetes is not fully controlled by insulin glargine with or without metformin and/or pioglitazone.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Eli Lilly and Company
Treatments:
Exenatide
Insulin
Insulin Glargine